1. Dr Roland Haag, you are the Managing Director of Galvita in Basel. Would you briefly explain who Galvita is?
Galvita AG is a pharmaceutical technology start-up founded in Basel in 2020 (www.galvita.com). We currently number 13 employees and develop, produce and market innovative oral dosage forms (tablets) that address patient needs such as fast action, taste masking and swallowing difficulties. To that end, Galvita has developed a technology platform with an innovative material (TIP–Template Inverted Particles), which can be loaded with many active agents and used by pharmaceutical companies and other industries.
2. What does your concept entail, and what are your goals?
Galvita licenses its technology to companies in the pharmaceutical, phytopharmaceutical, nutraceutical and veterinary sectors. In addition, Galvita assists its contract manufacturers with technical and clinical feasibility and pilot studies and with scale-up for larger production volumes.
Our goal is to be seen as a development partner of choice by our international customers, for example the pharmaceutical industry, when it comes to oral formulations for children and elderly patients.